Drug research

Tipifarnib

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as R115777; Zarnesta; Zarnestra

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyNCT02464228	KURA	Phase 2	Completed	2021-03-31Actual
Tipifarnib in Subjects With Myelodysplastic SyndromesNCT02779777	KURA	Phase 2	Terminated	2018-08-28Actual
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsNCT02383927	KURA	Phase 2	Completed	2020-12-14Actual
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaNCT02807272	KURA	Phase 2	Completed	2020-11-30Actual
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyNCT03719690	KURA	Phase 2	Completed	2023-05-02Actual

KURACompletedPrimary completion: 2021-03-31 · Actual

Trial details

KURATerminatedPrimary completion: 2018-08-28 · Actual

Trial details

KURACompletedPrimary completion: 2020-12-14 · Actual

Trial details

KURACompletedPrimary completion: 2020-11-30 · Actual

Trial details

KURACompletedPrimary completion: 2023-05-02 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.